C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 148 institutions reported holding it in 13F filings for Q2 2026, worth $547.9M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:56 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $105.0M (292.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Jan 14, 2025 | Feb 22, 2024 | Feb 23, 2023 | Jan 10, 2022 |
| Revenue | $35.9M | $35.6M | $20.8M | $31.1M | – |
| Operating expenses | $151.2M | $155.2M | $159.8M | $160.6M | $127.9M |
| Research and development | $104.2M | $110.6M | $117.7M | $117.8M | $94.7M |
| Selling, general and administrative | $36.2M | $42.1M | $42.1M | $42.8M | $33.3M |
| Operating income | -$115.2M | -$119.6M | -$139.0M | -$129.5M | -$82.1M |
| Income tax | $121.0K | $131.0K | $1.28M | $0 | – |
| Net income | -$105.0M | -$105.3M | -$132.5M | -$128.2M | -$83.9M |
| EPS, basic | $-1.27 | $-1.52 | $-2.67 | $-2.62 | $-1.82 |
| EPS, diluted | $-1.27 | $-1.52 | $-2.67 | $-2.62 | – |
| Weighted shares, basic | 82.9M | 69.4M | 49.6M | 48.9M | – |
| Weighted shares, diluted | 82.9M | 69.4M | 49.6M | 48.9M | – |
| Margins and growth | |||||
| Operating margin | -320.5% | -336.1% | -669.8% | -416.6% | – |
| Net margin | -292.1% | -296.0% | -638.3% | -412.2% | – |
| Revenue growth, year over year | +1.0% | +71.4% | −33.3% | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Jan 14, 2025 | Feb 22, 2024 | Feb 23, 2023 | Jan 10, 2022 |
| Cash and equivalents | $74.6M | $55.5M | $126.6M | $29.8M | $76.1M |
| Short-term investments | – | – | – | – | $233.2M |
| Accounts receivable | $2.40M | $3.10M | $11.8M | $1.47M | $5.72M |
| Total current assets | $258.1M | $257.8M | $271.2M | $287.6M | $325.7M |
| Property, plant and equipment | $4.74M | $5.84M | $7.13M | $7.40M | $3.11M |
| Total assets | $359.1M | $349.6M | $376.5M | $430.8M | $506.8M |
| Accounts payable | $858.0K | $1.33M | $1.45M | $1.17M | $4.51M |
| Short-term debt | – | – | $0 | $2.29M | – |
| Total current liabilities | $33.0M | $45.2M | $42.8M | $44.5M | $51.2M |
| Long-term debt | – | – | $0 | $9.20M | $10.8M |
| Total liabilities | $102.5M | $133.6M | $130.3M | $141.6M | $117.2M |
| Shareholders' equity | $256.6M | $216.0M | $246.1M | $289.2M | $389.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Jan 14, 2025 | Feb 22, 2024 | Feb 23, 2023 | Jan 10, 2022 |
| Operating cash flow | -$98.7M | -$65.2M | -$106.8M | -$105.9M | -$87.0M |
| Capital expenditures | $607.0K | $180.0K | $1.71M | $5.50M | $1.28M |
| Free cash flow | -$99.3M | -$65.3M | -$108.5M | -$111.4M | -$88.2M |
| Depreciation and amortization | $1.96M | $1.82M | $1.88M | $1.68M | $1.49M |
| Stock-based compensation | $19.1M | $29.7M | $27.2M | $30.0M | $21.5M |
| Share buybacks | $193.0K | $194.0K | $110.0K | – | – |
| Investing cash flow | -$8.60M | -$51.3M | $158.3M | $58.4M | -$189.3M |
| Financing cash flow | $126.4M | $45.3M | $45.5M | $1.15M | $171.4M |
| Net change in cash | $19.1M | -$71.1M | $97.0M | -$46.4M | – |
| Ratio | |||||
| Stock-based compensation, % of revenue | 53.1% | 83.4% | 131.2% | 96.5% | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 131.3M | +35.5% | SEC |
| Jul 31, 2026 | 123.0M | +72.9% | SEC |
| May 1, 2026 | 110.6M | +55.7% | SEC |
| Feb 23, 2026 | 97.6M | +37.5% | SEC |
| Oct 29, 2025 | 96.9M | +37.3% | SEC |
| Jul 29, 2025 | 71.2M | +2.6% | SEC |
| May 1, 2025 | 71.0M | +3.2% | SEC |
| Feb 20, 2025 | 71.0M | +3.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.